Aurore Fayosse
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Aurore Fayosse has a total of 117 co-authors. Here are the top co-authors by number of shared publications:
- Archana Singh-Manoux
Université Paris Cité, INSERM U1153, Epidemiology of Ageing and Neurodegenerative Diseases (EpiAgeing), France
17 shared publications - Séverine Sabia
Université Paris Cité, INSERM U1153, Epidemiology of Ageing and Neurodegenerative Diseases (EpiAgeing), France
17 shared publications - Mika Kivimäki
Faculty of Brain Sciences, University College London, London, UK
10 shared publications - Aline Dugravot
INSERM, U1018, Centre for Research in Epidemiology and Population Health, Hôpital Paul Brousse, Villejuif, France
9 shared publications - Julien Dumurgier
Université Paris Cité, INSERM U1153, Epidemiology of Ageing and Neurodegenerative Diseases (EpiAgeing), France
8 shared publications Aline Dugravot
Université de Paris, Inserm U1153, Epidemiology of Ageing and Neurodegenerative diseases, France (A.G.-S., A.D., A.F., L.J., S.S., A.S.).
5 shared publications
Latest Publications
- Open Access
- 24 November 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (10) , e218681
Blood-Based Biomarkers as Predictors of All-Cause Dementia
Background and ObjectivesBlood-based biomarkers are strongly correlated with amyloid positivity in research settings, but their long-term performance in heterogeneous populations remains unclear. O...
- 24 November 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (10) , e218681
Open AccessBlood-Based Biomarkers as Predictors of All-Cause Dementia
Background and ObjectivesBlood-based biomarkers are strongly correlated with amyloid positivity in research settings, but their long-term performance in heterogeneous populations remains unclear. O...
- Open Access
- 12 June 2026
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 23 (6) , e1004914
Comparison of count-based and clustering definitions of multimorbidity and their association with prevalence of multimorbidity, health profiles, and mortality: A cohort study of UK Biobank participants
Background: Multimorbidity, the presence of several chronic conditions, is linked to higher mortality and healthcare use and thus poses a major challenge for aging populations. While most studies rely on simple counts of conditions, clustering approaches have been proposed to describe patterns of co-occurring diseases. We aimed to evaluate the extent to which these methodological choices influence prevalence and association with health profiles and mortality. Methods and findings: Using UK Biobank baseline data ( n = 474,397), collected between 2006 and 2010, we compared six count-based definitions of multimorbidity based on different condition lists (extended, most prevalent, or body systems) and thresholds (≥2 versus ≥3 conditions). We also applied a clustering analysis to characterize subtypes of multimorbidity among participants with at least two chronic conditions. We compared prevalence and associations with concurrent health outcomes (polypharmacy, self-rated health, frailty, falls, surgery, chronic pain), blood-based measures (C-reactive protein, Cystatin-C, HDL, LDL Cholesterol, IGF-1), and 3- and 10-year mortality risks. Analyses were undertaken separately in men and women using multivariable regression models adjusted for sociodemographic characteristics and body mass index. Multimorbidity prevalence ranged from 1.0% (cluster-based) to 35.3% (count-based). Count-based definitions using lists with more conditions yielded higher prevalence. Higher thresholds identified more severe health profiles on all measured health outcomes, blood-based measures, but not higher mortality risks. Associations with blood-based measures were more pronounced using clustering, with the highest differences from the standard definition distributed across clusters. Odds ratios for 3-year mortality ranged from 1.44 [1.26; 1.64] to 4.60 [3.73; 5.62] for men and 1.35 [1.07; 1.69] to 3.83 [2.78; 5.14] for women. For 10-year mortality, they ranged from 1.42 [1.34; 1.50] to 3.86 [3.46; 4.30] in men and 1.29 [1.21; 1.39] to 3.33 [2.93; 3.77] for women, with clustering identifying groups with low prevalence and high mortality risks. Findings should be interpreted in light of the selected nature of the UK Biobank cohort and the cross-sectional assessment of several health indicators. Conclusion: Operational definitions of multimorbidity substantially influence prevalence estimates, while associations with mortality appear more robust across count-based approaches. Clustering analyses provide complementary insights into heterogeneity within multimorbid populations. Future translational studies are warranted to determine how multimorbidity definitions can be optimized to ultimately improve clinical management and health outcomes in practice.
- 12 June 2026
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 23 (6) , e1004914
Open AccessComparison of count-based and clustering definitions of multimorbidity and their association with prevalence of multimorbidity, health profiles, and mortality: A cohort study of UK Biobank participants
Background: Multimorbidity, the presence of several chronic conditions, is linked to higher mortality and healthcare use and thus poses a major challenge for aging populations. While most studies rely on simple counts of conditions, clustering approaches have been proposed to describe patterns of co-occurring diseases. We aimed to evaluate the extent to which these methodological choices influence prevalence and association with health profiles and mortality. Methods and findings: Using UK Biobank baseline data ( n = 474,397), collected between 2006 and 2010, we compared six count-based definitions of multimorbidity based on different condition lists (extended, most prevalent, or body systems) and thresholds (≥2 versus ≥3 conditions). We also applied a clustering analysis to characterize subtypes of multimorbidity among participants with at least two chronic conditions. We compared prevalence and associations with concurrent health outcomes (polypharmacy, self-rated health, frailty, falls, surgery, chronic pain), blood-based measures (C-reactive protein, Cystatin-C, HDL, LDL Cholesterol, IGF-1), and 3- and 10-year mortality risks. Analyses were undertaken separately in men and women using multivariable regression models adjusted for sociodemographic characteristics and body mass index. Multimorbidity prevalence ranged from 1.0% (cluster-based) to 35.3% (count-based). Count-based definitions using lists with more conditions yielded higher prevalence. Higher thresholds identified more severe health profiles on all measured health outcomes, blood-based measures, but not higher mortality risks. Associations with blood-based measures were more pronounced using clustering, with the highest differences from the standard definition distributed across clusters. Odds ratios for 3-year mortality ranged from 1.44 [1.26; 1.64] to 4.60 [3.73; 5.62] for men and 1.35 [1.07; 1.69] to 3.83 [2.78; 5.14] for women. For 10-year mortality, they ranged from 1.42 [1.34; 1.50] to 3.86 [3.46; 4.30] in men and 1.29 [1.21; 1.39] to 3.33 [2.93; 3.77] for women, with clustering identifying groups with low prevalence and high mortality risks. Findings should be interpreted in light of the selected nature of the UK Biobank cohort and the cross-sectional assessment of several health indicators. Conclusion: Operational definitions of multimorbidity substantially influence prevalence estimates, while associations with mortality appear more robust across count-based approaches. Clustering analyses provide complementary insights into heterogeneity within multimorbid populations. Future translational studies are warranted to determine how multimorbidity definitions can be optimized to ultimately improve clinical management and health outcomes in practice.
- Open Access
Psychomotor retardation and risk of Parkinson's disease in unipolar depression: a retrospective cohort study
Background: Depression is associated with an increased risk of subsequent Parkinson's disease. Neuroimaging studies suggest a neurobiological overlap in mechanisms underlying Parkinson's disease and psychomotor retardation in depression. Our aim was to investigate whether, among individuals with depression, the presence of psychomotor retardation was associated with the development of subsequent Parkinson's disease. Methods: In a retrospective cohort study, electronic healthcare records from individuals diagnosed with depression at age 40 or over in a large mental health service in London, UK were examined for the presence of psychomotor retardation. Linkage to general hospital records was used to ascertain diagnoses of Parkinson's disease between 2007 and 2023. Cox regression was used to compare the hazard of Parkinson's disease in individuals with depression with and without psychomotor retardation. Results: Among 6327 patients with depression, 2402 (38.0%) had psychomotor retardation. The adjusted hazard ratio for development of Parkinson's in those with psychomotor retardation was 1.43 (95% CI 1.02 - 2.01, p = 0.04). Secondary analyses demonstrated a significant difference in psychomotor retardation incidence at least 10 years before Parkinson's diagnosis. Conclusions: Psychomotor retardation in later-life depression is associated with increased risk of subsequent Parkinson's diagnosis over an extended period of time, suggesting that the relationship cannot solely be explained by misdiagnosis. Psychomotor retardation may therefore serve as a marker of prodromal Parkinson's disease.
Open AccessPsychomotor retardation and risk of Parkinson's disease in unipolar depression: a retrospective cohort study
Background: Depression is associated with an increased risk of subsequent Parkinson's disease. Neuroimaging studies suggest a neurobiological overlap in mechanisms underlying Parkinson's disease and psychomotor retardation in depression. Our aim was to investigate whether, among individuals with depression, the presence of psychomotor retardation was associated with the development of subsequent Parkinson's disease. Methods: In a retrospective cohort study, electronic healthcare records from individuals diagnosed with depression at age 40 or over in a large mental health service in London, UK were examined for the presence of psychomotor retardation. Linkage to general hospital records was used to ascertain diagnoses of Parkinson's disease between 2007 and 2023. Cox regression was used to compare the hazard of Parkinson's disease in individuals with depression with and without psychomotor retardation. Results: Among 6327 patients with depression, 2402 (38.0%) had psychomotor retardation. The adjusted hazard ratio for development of Parkinson's in those with psychomotor retardation was 1.43 (95% CI 1.02 - 2.01, p = 0.04). Secondary analyses demonstrated a significant difference in psychomotor retardation incidence at least 10 years before Parkinson's diagnosis. Conclusions: Psychomotor retardation in later-life depression is associated with increased risk of subsequent Parkinson's diagnosis over an extended period of time, suggesting that the relationship cannot solely be explained by misdiagnosis. Psychomotor retardation may therefore serve as a marker of prodromal Parkinson's disease.
- Open Access
Mental health symptoms as preclinical indicators of dementia: a Whitehall II cohort study
INTRODUCTION: Changes in mental health symptoms, and their timing in the preclinical period of dementia, are not well characterised. METHODS: We followed 5,495 Whitehall II participants (median age 68.5; 72.1% male) from their mental health symptoms assessment using the Clinical Interview Schedule-Revised (CIS-R) starting in 2012/13 to dementia diagnosis, death, or 2024. Linear mixed effects regression assessed CIS-R score changes preceding dementia. Flexible parametric models estimated associations of mental health symptoms with dementia. RESULTS: Total CIS-R score increased (2.56 points [0.85-4.27]) in the 12 years preceding dementia. Having any mental health condition was associated with dementia in the short-term (HR at 3 years=4.04 [2.53-6.50]) but not the long-term (HR at 6 years=1.26 [0.63-2.49]). This pattern held for severe mental health conditions, concentration problems, depression, irritability, fatigue, anxiety, and worry. DISCUSSION: Awareness of mental health symptoms as preclinical indicators of dementia in the short-term may support timely diagnosis of dementia.
Open AccessMental health symptoms as preclinical indicators of dementia: a Whitehall II cohort study
INTRODUCTION: Changes in mental health symptoms, and their timing in the preclinical period of dementia, are not well characterised. METHODS: We followed 5,495 Whitehall II participants (median age 68.5; 72.1% male) from their mental health symptoms assessment using the Clinical Interview Schedule-Revised (CIS-R) starting in 2012/13 to dementia diagnosis, death, or 2024. Linear mixed effects regression assessed CIS-R score changes preceding dementia. Flexible parametric models estimated associations of mental health symptoms with dementia. RESULTS: Total CIS-R score increased (2.56 points [0.85-4.27]) in the 12 years preceding dementia. Having any mental health condition was associated with dementia in the short-term (HR at 3 years=4.04 [2.53-6.50]) but not the long-term (HR at 6 years=1.26 [0.63-2.49]). This pattern held for severe mental health conditions, concentration problems, depression, irritability, fatigue, anxiety, and worry. DISCUSSION: Awareness of mental health symptoms as preclinical indicators of dementia in the short-term may support timely diagnosis of dementia.
- Open Access
- 13 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1)
Circadian rhythm profiles derived from accelerometer measures of the sleep-wake cycle in two cohort studies
Accelerometers allow objective measures of dimensions (rest-activity rhythm (RAR), daytime activity, sleep, and chronotype) of the bio-behavioural manifestation of circadian rhythm (CR) using multiple metrics in large-scale studies. These dimensions are rarely examined together due to methodological challenges of using correlated data. To address this challenge, we propose a two-step approach consisting of data reduction of CR metrics using principal component analyses, followed by k-means clustering to identify groups of individuals with a similar profile using data from the Whitehall II (N = 3,991, mean age=69.4years) and UK Biobank (N = 54,995, mean age=67.5years) cohort studies. Our analyses identified nine CR clusters: two presented extreme (most robust/poorest) RAR and (highest/lowest) daytime activity, two robust RAR with opposite sleep profiles (longer and efficient/shorter and fragmented), one high-intensity physical activity, and four poor RAR (one characterised by late chronotype, two by low activity but opposite sleep profiles, and one by restless (agitated) sleep). The participants in these nine clusters differed on sociodemographic, behavioural and health-related factors. Findings were similar in these two independent cohort studies, highlighting the validity of our approach. Most previous studies have used only the RAR dimension of circadian rhythm, and here we show that this might be an oversimplification as demonstrated by nine clusters characterised by combinations of RAR, daytime activity, sleep, and chronotype. Our innovative approach demonstrates feasibility of using all dimensions to study the impact of circadian rhythm dysregulation on health.
- 13 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1)
Open AccessCircadian rhythm profiles derived from accelerometer measures of the sleep-wake cycle in two cohort studies
Accelerometers allow objective measures of dimensions (rest-activity rhythm (RAR), daytime activity, sleep, and chronotype) of the bio-behavioural manifestation of circadian rhythm (CR) using multiple metrics in large-scale studies. These dimensions are rarely examined together due to methodological challenges of using correlated data. To address this challenge, we propose a two-step approach consisting of data reduction of CR metrics using principal component analyses, followed by k-means clustering to identify groups of individuals with a similar profile using data from the Whitehall II (N = 3,991, mean age=69.4years) and UK Biobank (N = 54,995, mean age=67.5years) cohort studies. Our analyses identified nine CR clusters: two presented extreme (most robust/poorest) RAR and (highest/lowest) daytime activity, two robust RAR with opposite sleep profiles (longer and efficient/shorter and fragmented), one high-intensity physical activity, and four poor RAR (one characterised by late chronotype, two by low activity but opposite sleep profiles, and one by restless (agitated) sleep). The participants in these nine clusters differed on sociodemographic, behavioural and health-related factors. Findings were similar in these two independent cohort studies, highlighting the validity of our approach. Most previous studies have used only the RAR dimension of circadian rhythm, and here we show that this might be an oversimplification as demonstrated by nine clusters characterised by combinations of RAR, daytime activity, sleep, and chronotype. Our innovative approach demonstrates feasibility of using all dimensions to study the impact of circadian rhythm dysregulation on health.
- Open Access
- 1 July 2025
- Published by Springer Nature in Nature Aging
- Vol. 5 (9) , 1-7
Association of midlife hearing impairment and hearing aid use with incident dementia: analysis of two UK-based longitudinal cohort studies
The prevalence of hearing impairment and dementia increases with age but the nature of their association remains unclear. Using data from two large UK-based cohort studies, we examined the longitudinal association of ‘midlife’ hearing impairment and hearing aid use with incident dementia. We found modest associations and population attributable fractions for reported and measured ‘midlife’ hearing impairment, highlighting the need to consider age at measurement of risk factors in studies that target dementia prevention.
- 1 July 2025
- Published by Springer Nature in Nature Aging
- Vol. 5 (9) , 1-7
Open AccessAssociation of midlife hearing impairment and hearing aid use with incident dementia: analysis of two UK-based longitudinal cohort studies
The prevalence of hearing impairment and dementia increases with age but the nature of their association remains unclear. Using data from two large UK-based cohort studies, we examined the longitudinal association of ‘midlife’ hearing impairment and hearing aid use with incident dementia. We found modest associations and population attributable fractions for reported and measured ‘midlife’ hearing impairment, highlighting the need to consider age at measurement of risk factors in studies that target dementia prevention.
- Open Access
- 17 January 2022
- Published by Oxford University Press (OUP) in Age and Ageing
- Vol. 51 (1)
Association between kidney function and incidence of dementia: 10-year follow-up of the Whitehall II cohort study
Background: Cognitive dysfunction is common in haemodialysis patients but whether poor kidney function in the general population is also associated with higher risk of dementia remains unclear. Objective: To examine the association of kidney function with incident dementia in community dwelling older adults. Design: Whitehall II prospective study. Setting: Population-based study on 6,050 adults, mean age 65.8 in 2007–2009. Methods: Poor kidney function, defined as estimated Glomerular Filtration Rate (eGFR) <60 ml/min/1.73 m2 in 2007–2009, and adverse change in eGFR was defined as decrease ≥4 ml/min/1.73 m2 between 2007–2009 and 2012–2013. Incident dementia was ascertained through linkage to electronic health records, and Cox regression was used to examine associations with dementia. Results: A total of 306 cases of dementia were recorded over a mean follow-up of 10 years. Baseline eGFR <60 was associated with a hazard ratio (HR) for dementia of 1.37 (95% CI 1.02, 1.85) in analysis adjusted for sociodemographic factors, hypertension, obesity, stroke, diabetes and cardiovascular disease/medication. Removing stroke cases at baseline and censoring them over the follow-up yielded an HR of 1.42 (95% CI 1.00, 2.00) for the association between CKD and dementia. Decline of eGFR ≥4 between 2007–2009 and 2012–2013 was associated with incidence of dementia over a 6.3 year mean follow-up (HR: 1.37; 95% CI 1.02, 1.85), with somewhat stronger associations when analyses were restricted to those with eGFR ≥60 in 2007–2009 (1.56; 95% CI: 1.12, 2.19). Conclusion: Poor and declining kidney function in older adults is associated with a higher risk of dementia that is not attributable to stroke and persists after accounting for major cardiometabolic conditions.
- 17 January 2022
- Published by Oxford University Press (OUP) in Age and Ageing
- Vol. 51 (1)
Open AccessAssociation between kidney function and incidence of dementia: 10-year follow-up of the Whitehall II cohort study
Background: Cognitive dysfunction is common in haemodialysis patients but whether poor kidney function in the general population is also associated with higher risk of dementia remains unclear. Objective: To examine the association of kidney function with incident dementia in community dwelling older adults. Design: Whitehall II prospective study. Setting: Population-based study on 6,050 adults, mean age 65.8 in 2007–2009. Methods: Poor kidney function, defined as estimated Glomerular Filtration Rate (eGFR) <60 ml/min/1.73 m2 in 2007–2009, and adverse change in eGFR was defined as decrease ≥4 ml/min/1.73 m2 between 2007–2009 and 2012–2013. Incident dementia was ascertained through linkage to electronic health records, and Cox regression was used to examine associations with dementia. Results: A total of 306 cases of dementia were recorded over a mean follow-up of 10 years. Baseline eGFR <60 was associated with a hazard ratio (HR) for dementia of 1.37 (95% CI 1.02, 1.85) in analysis adjusted for sociodemographic factors, hypertension, obesity, stroke, diabetes and cardiovascular disease/medication. Removing stroke cases at baseline and censoring them over the follow-up yielded an HR of 1.42 (95% CI 1.00, 2.00) for the association between CKD and dementia. Decline of eGFR ≥4 between 2007–2009 and 2012–2013 was associated with incidence of dementia over a 6.3 year mean follow-up (HR: 1.37; 95% CI 1.02, 1.85), with somewhat stronger associations when analyses were restricted to those with eGFR ≥60 in 2007–2009 (1.56; 95% CI: 1.12, 2.19). Conclusion: Poor and declining kidney function in older adults is associated with a higher risk of dementia that is not attributable to stroke and persists after accounting for major cardiometabolic conditions.
- 1 January 2022
- Published by Wolters Kluwer Health in Stroke
- Vol. 53 (1) , 228-237
Long-Term Evolution of Functional Limitations in Stroke Survivors Compared With Stroke-Free Controls: Findings From 15 Years of Follow-Up Across 3 International Surveys of Aging
Background and Purpose: In the chronic phase 2 to 5 years poststroke, limitations in activities of daily living (ADL) and instrumental ADL (IADL) initially plateau before steady increasing. However, the impact of age and differences in initial levels of disability on the evolution of these limitations remains unclear. As such, this study aims to evaluate differences in long-term evolution of ADL/IADL limitations between stroke survivors and stroke-free population, and how limitations differ by initial level of disability for stroke survivors. Methods: Thirty-three thousand six hundred sixty participants (5610 first-ever stroke cases with no recurrence during follow-up and 28 050 stroke-free controls) aged ≥50 from the Health and Retirement Study, Survey of Health, Ageing and Retirement in Europe, and English Longitudinal Study of Ageing were assessed for number of ADL/IADL limitations during the poststroke chronic phase (for cases) and over follow-up years 1996 to 2018 (for controls). Three thousand seven hundred eighteen stroke cases were additionally categorized by disability level using the modified Rankin Scale score of 1 to 2 years poststroke. Evolution of ADL/IADL limitations was assessed in stroke cases and controls and by modified Rankin Scale score (0–1, 2–3, 4–5) using linear mixed models. Models were stratified by age group (50–74 and ≥75 years) and adjusted for baseline characteristics, health behaviors, BMI, and comorbidities. Results: Findings showed relative stability of ADL/IADL limitations during 3 to 6 years poststroke followed by an increase for both populations, which was faster for younger stroke cases, suggesting a differential age-effect ( P <0.001). Disability level at 1 to 2 years poststroke influenced the evolution of limitations over time, especially for severe disability (modified Rankin Scale score, 4–5) associated with a reduction in limitations at 5 to 6 years poststroke. Conclusions: Our findings showed that during the poststroke chronic phase functional limitations first plateau and then increase and the evolution differs by disability severity. These results highlight the importance of adaptive long-term health and social care measures for stroke survivors.
- 1 January 2022
- Published by Wolters Kluwer Health in Stroke
- Vol. 53 (1) , 228-237
Long-Term Evolution of Functional Limitations in Stroke Survivors Compared With Stroke-Free Controls: Findings From 15 Years of Follow-Up Across 3 International Surveys of Aging
Background and Purpose: In the chronic phase 2 to 5 years poststroke, limitations in activities of daily living (ADL) and instrumental ADL (IADL) initially plateau before steady increasing. However, the impact of age and differences in initial levels of disability on the evolution of these limitations remains unclear. As such, this study aims to evaluate differences in long-term evolution of ADL/IADL limitations between stroke survivors and stroke-free population, and how limitations differ by initial level of disability for stroke survivors. Methods: Thirty-three thousand six hundred sixty participants (5610 first-ever stroke cases with no recurrence during follow-up and 28 050 stroke-free controls) aged ≥50 from the Health and Retirement Study, Survey of Health, Ageing and Retirement in Europe, and English Longitudinal Study of Ageing were assessed for number of ADL/IADL limitations during the poststroke chronic phase (for cases) and over follow-up years 1996 to 2018 (for controls). Three thousand seven hundred eighteen stroke cases were additionally categorized by disability level using the modified Rankin Scale score of 1 to 2 years poststroke. Evolution of ADL/IADL limitations was assessed in stroke cases and controls and by modified Rankin Scale score (0–1, 2–3, 4–5) using linear mixed models. Models were stratified by age group (50–74 and ≥75 years) and adjusted for baseline characteristics, health behaviors, BMI, and comorbidities. Results: Findings showed relative stability of ADL/IADL limitations during 3 to 6 years poststroke followed by an increase for both populations, which was faster for younger stroke cases, suggesting a differential age-effect ( P <0.001). Disability level at 1 to 2 years poststroke influenced the evolution of limitations over time, especially for severe disability (modified Rankin Scale score, 4–5) associated with a reduction in limitations at 5 to 6 years poststroke. Conclusions: Our findings showed that during the poststroke chronic phase functional limitations first plateau and then increase and the evolution differs by disability severity. These results highlight the importance of adaptive long-term health and social care measures for stroke survivors.
- Open Access
- 22 April 2021
- Published by MDPI AG in Diagnostics
- Vol. 11 (5) , 754
Neurofilaments as Emerging Biomarkers of Neuroaxonal Damage to Differentiate Behavioral Frontotemporal Dementia from Primary Psychiatric Disorders: A Systematic Review
The behavioral variant of frontotemporal dementia (bvFTD) is a clinical syndrome resulting from various causes of neuronal demises associated with frontotemporal lobar degeneration. Symptoms include behavioral and personality changes, social cognitive impairment, and executive function deficits. There is a significant clinical overlap between this syndrome and various primary psychiatric disorders (PPD). Structural and functional neuroimaging are considered helpful to support the diagnosis of bvFTD, but their sensitivity and specificity remain imperfect. There is growing evidence concerning the potential of neurofilaments as biomarkers reflecting axonal and neuronal lesions. Ultrasensitive analytic platforms have recently enabled neurofilament light chains’ (NfL) detection not only from cerebrospinal fluid but also from peripheral blood samples in FTD patients. In this short review, we present recent advances and perspectives for the use of NfL assessments as biomarkers of neuroaxonal damage to differentiate bvFTD from primary psychiatric disorders.
- 22 April 2021
- Published by MDPI AG in Diagnostics
- Vol. 11 (5) , 754
Open AccessNeurofilaments as Emerging Biomarkers of Neuroaxonal Damage to Differentiate Behavioral Frontotemporal Dementia from Primary Psychiatric Disorders: A Systematic Review
The behavioral variant of frontotemporal dementia (bvFTD) is a clinical syndrome resulting from various causes of neuronal demises associated with frontotemporal lobar degeneration. Symptoms include behavioral and personality changes, social cognitive impairment, and executive function deficits. There is a significant clinical overlap between this syndrome and various primary psychiatric disorders (PPD). Structural and functional neuroimaging are considered helpful to support the diagnosis of bvFTD, but their sensitivity and specificity remain imperfect. There is growing evidence concerning the potential of neurofilaments as biomarkers reflecting axonal and neuronal lesions. Ultrasensitive analytic platforms have recently enabled neurofilament light chains’ (NfL) detection not only from cerebrospinal fluid but also from peripheral blood samples in FTD patients. In this short review, we present recent advances and perspectives for the use of NfL assessments as biomarkers of neuroaxonal damage to differentiate bvFTD from primary psychiatric disorders.